JBC Focus on PI3-Kinase with Echelon

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertsch, U.
Right arrow Articles by Mayr, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertsch, U.
Right arrow Articles by Mayr, G. W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 3, 1557-1564, January 21, 2000


The Second Messenger Binding Site of Inositol 1,4,5-Trisphosphate 3-Kinase Is Centered in the Catalytic Domain and Related to the Inositol Trisphosphate Receptor Site*

Uwe Bertsch, Christina DeschermeierDagger , Werner Fanick, Irute Girkontaite§, Kirsten Hillemeier, Heiko Johnen, Wolfgang Weglöhner, Frank Emmrichpar , and Georg W. Mayr**

From the Institut für Medizinische Biochemie und Molekularbiologie, Universitäts-Krankenhaus Eppendorf, Martinistrasse 52, D-20246 Hamburg, the § Institut für Medizinische Strahlenkunde und Zellforschung, Universität Würzburg, Versbacher Strasse 5, D-97078 Würzburg,  Brahms Diagnostica, Komturstrasse 19-20, D-12099 Berlin, and the par  Institut für Klinische Immunologie und Transfusionsmedizin, Universitätsklinik Leipzig, Linnéstrasse 3, D-04103 Leipzig, Germany

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A segment of inositol 1,4,5-trisphosphate 3-kinase responsible for inositol 1,4,5-trisphosphate (InsP3) binding was characterized and confirmed by three different approaches employing the fully active expressed catalytic domain of the enzyme. Part of this moiety was protected from limited tryptic proteolysis by InsP3. Sequencing of two fragments of 16 and 21 kDa, generated in the absence or presence of InsP3, respectively, identified segment Glu-271 to Arg-305 as being protected. 15 monoclonal antibodies, all binding to epitopes within this region, inhibited enzyme activity and interfered with inositol phosphate binding. Detailed enzyme kinetic parameters of 32 site-directed mutants revealed residues Arg-276 and Lys-303 in this segment and Arg-322, located nearby, as directly involved in and five other closely neighbored residues, all located within a segment of 73 amino acids, as also influencing InsP3 binding. Part of this region is similar in sequence to an InsP3 binding segment in InsP3 receptors. Combined with the finding that mutants influencing only ATP binding all lie outside this region, these data indicate that an InsP3 binding core domain is inserted between two segments acting together in ATP binding and phosphate transfer.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The second messenger inositol 1,4,5-trisphosphate (InsP3)1 is phosphorylated by a 3-kinase to inositol 1,3,4,5-tetrakisphosphate (InsP4). Recently this product has received attention because of a growing number of discovered biological functions such as regulation of GTPase-activating proteins (1) and vesicle formation/fusion by adapter protein binding (for review, see Refs. 2 and 3). Inositol 1,4,5-trisphosphate 3-kinase (IP3K) is one of the few enzymes that bind InsP3 with high affinity and high selectivity. How this combination of affinity and selectivity is achieved by InsP3-binding proteins is largely unknown to date, as are the structural requirements for highly selective InsP3 binding.

The most prominent InsP3-binding protein is the InsP3 receptor (IP3R), a tetrameric Ca2+ channel residing in the endoplasmic reticulum, of which three isoenyzmes, types I-III, have been characterized on the cDNA level (4-6) (for review, see Ref. 7). For the IP3R the InsP3 binding domain has been confined to the amino-terminal 580 amino acids, with a minimal binding moiety of 353 amino acids (amino acids 226-578), displaying somewhat reduced affinity for InsP3 (8). Particularly, three conserved basic amino acids have been pointed out by site-directed mutagenesis as being involved in ligand binding (8). Furthermore, photoaffinity labeling with InsP3 analogs identified a peptide comprising amino acids 476-501 of the IP3R as being part of the InsP3 binding site (9).

Besides the IP3R some members of a family of inositol polyphosphate/inositol phospholipid 5-phosphatases are also capable of binding to InsP3 with high affinity (for review, see Refs. 10 and 11). An InsP3 binding segment has been located in the catalytic domain of type II inositol polyphosphate 5-phosphatases, with two short, highly conserved amino acid motifs (WXGDXNXR and PXWCDRXL) identified by mutational analysis as being involved in catalysis and/or substrate binding (12). Particularly the arginine residue (Arg-480; bold above) was found to increase the enzyme's Km for InsP3, reflecting a reduced affinity for InsP3 (12).

Two further proteins, which do not metabolize InsP3, have been found to bind it by experiments using photoaffinity analogs and specific affinity purification (13). One of these proteins was identified by peptide sequencing as phospholipase Cdelta 1, and the other one was found to be closely related to phospholipase Cdelta 1, although lacking any detectable phospholipase C activity (14). Only for phospholipase Cdelta 1 the structural requirements for InsP3 binding are already fairly well understood because the pleckstrin homology domain of this enzyme (amino acids 17-132) has been identified as the InsP3-binding element, and a crystal structure of this domain bound to InsP3 has been obtained (15). Within the NH2-terminal part of the pleckstrin homology domain (amino acids 17-60) five basic, one acidic, and one aromatic amino acid were identified as being directly involved in InsP3 binding (15). Two further basic amino acids within this protein segment were found to be indirectly involved in binding by site-directed mutation.

IP3K is known as a highly selective InsP3-binding protein (16) with high affinity for this substrate, as illustrated by Km values ranging from 0.7 to 3.1 µM (17-21) depending on the source and isoform examined. Several cDNAs for this enzyme have been cloned, e.g. three different isoforms, designated A---C, from human (Refs. 22, 23, and GenBank accession no. D38169), two isoforms from rat (24-26), and one isoform from chicken (21). In the nematode worm Caenorhabditis elegans one gene for IP3K has been identified, which is alternatively spliced into three different mRNAs (27).

The catalytic domain of the enzyme has been mapped to the C terminus with the last 275 amino acids being indispensable for enzyme activity (28). This domain also shows the highest degree of amino acid conservation (30% identities) between isoforms and between species. Within this region Lys-197 and Asp-414 have been found to be involved in ATP binding in rat isoform A by site-directed mutagenesis (29). A recent study has gathered evidence for the involvement of one lysine residue (Lys-262) in rat isoform A (30) in InsP3 binding.

Here we demonstrate that in the chicken IP3K A-isoform a 35-amino acid region (amino acids 271-305) is protected against tryptic cleavage after InsP3 binding and that monoclonal antibodies recognizing epitopes within this region have inhibitory effects on the enzyme activity and interfere with InsP4 binding to the enzyme. Moreover, the enzymatic properties of recombinantly expressed mutant proteins clearly indicate the direct involvement in InsP3 binding of three residues (Arg-276 and Lys-303) within or close to this region (Arg-322) and a participation in binding of five neighbored residues, all lying within a 73-amino acid segment, centered in the catalytic domain.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning, Expression, and Purification of a GST-IP3K Fusion Protein-- A bacterial expression vector, designated pGEX-SE1, was constructed by ligation of a 570-base pair fragment from a polymerase chain reaction product (polymerase chain reactions 5 and 4 (21)), comprising amino acids 164-351 of chicken IP3K, into vector pGEX2T (Amersham Pharmacia Biotech, Freiburg). XL1 Blue bacteria transformed with pGEX-SE1 according to Ref. 31 were used for overexpression of the GST-IP3K fusion protein (Pharmacia GST fusion kit). After 2 h of induction of protein expression by 0.1 mM isopropyl-1-thio-beta -D-galactopyranoside, the culture was centrifuged at 5,000 × g for 10 min. The bacterial pellet was resuspended in 1/30 of the culture volume of phosphate-buffered saline and frozen at -20 °C. The subsequently thawed bacterial suspension was subjected to lysis by addition of the following components at the respective final concentrations: 0.5 mg/ml lysozyme, 0.1 mg/ml DNase I, 0.1% Triton X-100, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 0.5 mM DTT, and by incubation at 35 °C for 5 min followed by 20 min on ice. Fusion protein aggregated in inclusion bodies was pelleted by centrifugation at 10,000 × g for 10 min. The pellet was extracted once with 1/3 of the resuspension volume of detergent buffer (200 mM NaCl, 20 mM Tris-Cl, 2 mM EDTA, 1 mM DTT, 1% deoxycholate, 1% Nonidet P-40 at pH 7.5) and twice with the same volume of Triton buffer (20 mM Tris-Cl, 1 mM EDTA, 1 mM DTT, 0.5% Triton X-100 at pH 7.5) by vigorous vortexing for several minutes. The extracted pellet was solubilized in 1/3 of the resuspension volume of 8 M urea in water, centrifuged at 10,000 × g, and the supernatant dialyzed exhaustively against dialysis buffer (1 × phosphate-buffered saline, 0.5 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA, 0.1% Triton X-100). Most of the fusion protein precipitated again during dialysis and was collected by centrifugation at 10,000 × g. The pellet was solubilized again in 4 ml of 8 M urea and diluted 1:50 with dialysis buffer. The again dialyzed protein remained soluble and was supplemented with 0.1 mM phenylmethylsulfonyl fluoride, gently mixed with 0.5 ml of glutathione-Sepharose resin and incubated for 40 min at room temperature under repeated mixing. The resin was washed on a column with 3 × 10 ml of dialysis buffer. The bound GST-IP3K fusion protein was eluted in three 1-ml fractions using elution buffer (50 mM Tris-Cl, 10 mM glutathione, 100 mM NaCl, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM DTT, 1 mM EDTA, 0.1% Triton X-100, pH 7.5). For these steps the resin was kept for 40, 15, and 15 min at room temperature in elution buffer, respectively.

Generation of Monoclonal Antibodies against a GST-IP3K Fusion Protein-- Monoclonal antibodies were produced according to the technique in Ref. 32. A BALB/c mouse was injected on day 0 and day 15 intraperitoneally and subcutaneously with 10 µg of affinity-purified GST-IP3K fusion protein in complete and incomplete Freund's adjuvant, respectively. 53 days later the mouse was boosted with 100 µg of GST-IP3K fusion protein and 200 µg of double-stranded RNA intravenously and intraperitoneally. 3 days after the boost the splenocytes were fused with SP2/O myeloma cells.

Generation of COOH-terminal Truncated GST-IP3K Fusion Proteins for Epitope Mapping of Monoclonal Antibodies-- Plasmid pGEX-SE1 was modified for nested deletion of the IP3K coding fragment from its 3'-end by cleavage with AccI and TthIII and insertion of a double-stranded DNA fragment created from the complementary oligonucleotides ND1 (5'-CTCTAGAAAAGGTACCTGACTGACTGAACGT-3') and ND2 (5'-TCAGTCAGTCAGGTACCTTTTCTAGA-3') into the gap. The resulting plasmid pGEX-SE570 was cleaved with KpnI and XbaI and then subjected to a nested deletion reaction using the nested deletion kit of Amersham Pharmacia Biotech. The reaction products were used to transform competent XL1 Blue cells (Stratagene), and the resulting transformants were screened by plasmid minipreparation and restriction enzyme digest for the length of the IP3K coding region. Several truncated plasmids were selected and dideoxynucleotide sequenced (33) using an Applied Biosystems 377 automated Sequenator. Bacterial colonies harboring plasmids of interest were then cultured and induced for the expression of GST fusion proteins as described above. Lysates, prepared as described above, were directly used for SDS-PAGE and Western blotting.

Production of the Recombinant IP3K and Mutants in Escherichia coli-- A 306-amino acid fragment of chicken comprising CaM binding and catalytic domain, designated IP3K147-C, as well as the derived mutant proteins were overexpressed in E. coli BL21(DE3) bacteria transformed with plasmid pEGIK or mutated derivates thereof and purified on phosphocellulose and CaM-Sepharose as described (21).

Partial Proteolytic Cleavage of Recombinant IP3K-- For a time course of proteolysis, affinity-purified IP3K147-C at a concentration of 0.48 mg/ml was digested in a 50-µl volume at 30 °C in 50 mM sodium phosphate buffer, pH 7.8, with 0.01 mg/ml trypsin (sequencing grade) for up to 20 min. Trypsin was added from a 0.5 mg/ml stock solution in 1 mM HCl, and 10-µl samples were withdrawn from the reaction and stopped by mixing with 3.3 µl 4 × SDS-PAGE sample buffer (0.2 M Tris-Cl, pH 6.8, 15% glycerol, 8.6% SDS, 0.8 M mercaptoethanol, 0.4 mg/ml bromphenol blue) and immediate heating to 95 °C for 8 min. For experiments regarding the effects of substrates on proteolysis, either 1 mM ATP or 250 µM InsP3 or both were added to the same reaction buffer. The dependence of proteolysis on the InsP3 concentration was determined in parallel reactions (10 µl) containing 50 mM Tris-Cl, pH 7.5, 0.24 mg/ml IP3K, 0.01 mg/ml trypsin, and InsP3 varying from 0.5 to 100 µM. After 20 min the reaction was stopped as above. For the determination of NH2-terminal peptide sequences of proteolysis intermediates, samples separated by SDS-PAGE were blotted to polyvinylidene difluoride membranes (34), and immobilized protein bands were sequenced on an Applied Biosystems 470 A Sequenator.

Site-directed Mutagenesis of IP3K Catalytic Domain-- The mutagenesis of the catalytic domain of chicken IP3K was done essentially as described in Ref. 35. Either plasmid pEGIK (21) or plasmid pGEM-IP3K Xba/Sph, based on the vector pGEM3Z (Amersham Pharmacia Biotech) and containing a 460-base pair insert of chicken IP3K representing amino acids 147-299, was used as template. For the pGEM-IP3K Xba/Sph template, primers NP24 (5'-GACGTTGTAAAACGACGGCCAGTG-3') and RP24 (5'-AACAGCTATGACCATGATTACGCC-3') were used as flanking primers, whereas for the pEGIK template primers UB24 (5'-GAAGAGCTCACTGAAGCCCGTGAGAAACC-3') and UB40 (5'-CTGAGTGATCTCTCTAGAGAAGAAAGTTAGTTA-3') were used as flanking primers. All oligonucleotides were from MWG Biotech (Ebersberg, Germany). The resulting polymerase chain reaction products were ligated into appropriately digested plasmid vectors. E. coli XL1 Blue cells transformed with the ligation products were selected for positive transformants by plasmid minipreparation and restriction digests. Insert sequences were verified by dideoxynucleotide sequencing. Appropriate restriction fragments of mutated polymerase chain reaction products were ligated into plasmid pEGIK. For the expression of mutant proteins BL21(DE3) bacteria were transformed with these vectors.

Optical Enzyme Assay for Determination of Specific IP3K Activity and Km Values for Substrates of Recombinant IP3K and Mutants-- IP3K activity and the Km values for InsP3 were determined as described previously (21). The Km values for ATP were derived from initial rates with a saturating initial InsP3 concentration of 25 µM and varying initial concentrations of ATP (0.025-2 mM). Statistic testing was with t test for unpaired samples.

Western Blotting-- SDS-PAGE was done according to Ref. 36. Semidry Western blotting was performed essentially as described (34). For the simultaneous detection of immunoreactivity of all monoclonal antibodies against fragments of IP3K, a whole SDS-polyacrylamide gel was loaded with protein in a pocket covering the entire width of the gel. After blotting, the membranes were fixed in a multiwell chamber (Phase, Lübeck, Germany) allowing the simultaneous application of up to 20 primary antibody solutions for immunodecoration onto separate, sealed strips of the membrane, with each strip covering the entire separation length of the gel in the running direction. After incubation with primary antibodies on separate membrane strips, the membrane was treated as a whole with secondary antibody, washing, and staining solutions.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

InsP3 Protects a 35-Amino Acid Fragment of IP3K from Limited Proteolysis-- We subjected the recombinantly expressed catalytic domain of chicken IP3K147-C to a limited protease treatment in the absence or presence of ATP and InsP3 and analyzed the resulting proteolytic fragments on SDS-PAGE. In the absence of substrates, cleavage with trypsin resulted in the immediate formation of at least five distinct bands with slightly reduced apparent molecular masses (36-32 kDa) down to a more protease-resistant fragment of 31 kDa (Fig. 1A). The most prominent stable cleavage intermediate of lower molecular mass was a 16-kDa fragment that was formed shortly after the 31-kDa fragment. The same cleavage pattern was found if ATP was present in the reaction mix at a concentration of 1 mM (not shown). In contrast, the presence of 250 µM InsP3 led to the formation of a quite stable, prominent 21-kDa digestion intermediate, whereas the formation of the 16-kDa fragment was suppressed (Fig. 1B). Besides, a stabilization of a 31-kDa fragment occurred also. The same pattern of proteolytic fragments was observed when both substrates ATP (1 mM) and InsP3 (250 µM) were present (not shown). Amino-terminal peptide sequences of isolated proteolytic fragments were determined (Fig. 2). For the 31-kDa band two superimposed sequences with initial yields of 70 and 49 pmol, respectively, were found, which could be easily assigned to two fragments starting at Tyr-178 and Ala-191, respectively. The 21-kDa band yielded a single peptide sequence (initial yield 159 pmol) corresponding to a fragment starting at Glu-271. Two superimposed sequences were also found for the 16-kDa band, which could be attributed to two fragments starting at Tyr-306 and Glu-311 with initial yields of 78 and 63 pmol, respectively. The observed Mr values imply that all fragments are not or only minimally truncated at the COOH terminus of the catalytic domain. Therefore, a segment protected from cleavage by trypsin in the InsP3-bound state (i.e. the NH2-terminal part of the 21-kDa fragment which is not present in the 16-kDa band) comprises 35 amino acids ranging from Glu-271 to Arg-305 (Fig. 3). Using varying InsP3 concentrations during tryptic digestion, an EC50 value of 36 µM was derived for the inhibition of tryptic cleavage after residues Arg-305 and Arg-310 as detected by the percentage of 21-kDa fragment formed. An even lower EC50 value (2.6 µM) was found for the inhibition of cleavage after residue Arg-270 related to the percentage of 31-kDa band formation (Fig. 4).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Tryptic digests of recombinant chicken IP3K in presence and absence of substrates. Coomassie Blue-stained SDS-polyacrylamide gels loaded with samples from the time course of digestion with trypsin in the absence of InsP3 and ATP (panel A), in the presence of 250 µM InsP3 (panel B) are shown. The duration of digestion in minutes is given above the corresponding lanes. Lanes labeled M show molecular mass marker proteins with molecular masses given in the margin.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2.   NH2-terminal peptide sequences for proteolytic fragments of IP3K. Amounts of amino acids found during Edman degradation are shown. Closed and open circles represent different superimposed sequences, and corresponding amino acids are indicated by one-letter codes. Assignment was based on known IP3K sequences. Solid lines represent fitted linear regressions for the first sequence (closed circles) and broken lines for the second sequence (open circles).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 3.   Schematic representation of the sequence of the chicken IP3K fragments used in this study. Horizontal bars represent (from top): recombinantly expressed IP3K containing CaM binding and catalytic domain (first bar), three GST-IP3K fusion proteins generated by nested deletion (second through fourth bars), 21- and 16-kDa proteolytic fragments (fifth and sixth bars), and the full-length IP3K from chicken (seventh bar). The box hatched with vertical lines represents the NH2-terminal domain in the full-length protein; horizontal lines are the corresponding segment in the recombinant protein. The CaM binding domain is represented by a black box and the catalytic domain by a box with diagonal hatching. The numbers at the ends of each fragment denote the amino acid positions. Below, the amino acid sequence from residue 240 to 329 is given explicitly. The 35 amino acids protected against proteolysis by InsP3 binding are boxed. The amino acid segment recognized by most monoclonal antibodies is represented by a continuous black bar below, designated Epitope B; the segment recognized by six of the antibodies is represented by a discontinuous bar, designated Epitope A. Peptide sequences determined for the 21-kDa and the 16-kDa fragments are highlighted by gray background shadings. Amino acids exchanged by site-directed mutagenesis are indicated by bold characters. Arrows point to the amino acids that were used for exchange. Residues, where the mutation affected the steady-state kinetic parameters of the enzyme, are double underlined, and the corresponding amino acids used for exchange are underlined. Mutants leading to aberrant folding are indicated in italics. The entire InsP3 binding segment identified is shown by a horizontal two-headed arrow. The region of homology between InsP3 and InsP6 kinases is boxed with a broken line.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   Dependence of the protection against proteolysis on InsP3 concentration. In panel A the Coomassie-stained SDS-PAGE analyses of samples from identical tryptic digests of IP3K at varying InsP3 concentrations are compared. InsP3 concentrations in the digests are indicated above each lane in µM. Lane M contains molecular mass marker proteins with molecular masses indicated in the right margin. Lane C shows the undigested starting material. In panel B the percentages of the protected 21- and 31-kDa fragments after digest, as measured by densitometry, are plotted against the InsP3 concentration.

Monoclonal Antibodies Specific for Chicken IP3K Bind to Epitopes within the "InsP3-protected" Region and Show Partial Inhibitory Effect on IP3K Activity-- For 15 monoclonal mouse antibodies, generated against an IP3K fragment ranging from Thr-164 to Val-341 and designated Kin3-Kin17, the epitope location and their effect on enzyme activity were investigated. Western blot experiments with a set of NH2-terminally or COOH-terminally truncated IP3K fragments, generated either by tryptic digestion of IP3K147-C or by nested deletion of the coding sequence for a GST-IP3K fusion protein (see "Experimental Procedures"), revealed for all monoclonal antibodies only epitopes within the 35-amino acid segment protected by InsP3 against tryptic cleavage. All antibodies recognized the NH2-terminally truncated 21-kDa fragment starting at Glu-271 (Fig. 5B) and none the 16 kDa fragment starting at Tyr-306 (Fig. 5A). On the other hand, the COOH-terminally truncated fragment from Thr-164 to Glu-285 was recognized extremely weakly only by antibodies Kin4, -6, -9, and -17 (Fig. 5E). The fragment from Thr-164 to Leu-289, four amino acids longer, was recognized strongly by six antibodies (Kin4, -6, -9, -13, -15, and -17; Fig. 5D), whereas all antibodies reacted with the fragment from Thr-164 to Ala-317(Fig. 5C). The weak lower Mr bands appearing in Fig. 5E in the lanes of the antibodies Kin8, -11, -12, and -13 appear to be caused by cross-reactivity toward unrelated E. coli proteins, which are more prominent on this particular blot, since the staining sensitivity was enhanced in order to detect the weak specific reactivity toward the IP3K fusion protein. From this pattern of immunoreactivity we can conclude that the motif "VDPL" (position 286-289) is part of the epitopes recognized by six of the monoclonal antibodies and that their complete epitopes (epitope A) lie between Glu-271 and Leu-289. The epitope recognized by all other antibodies (epitope B) is contained within the segment from Ala-290 to Arg-305. A schematic representation is shown in Fig. 3.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 5.   Epitope characterization of monoclonal antibodies against chicken IP3K. Proteolytic fragments (panels A and B) of chicken IP3K and bacterially produced GST-IP3K fusion proteins in bacterial lysates (panels C---E) were probed simultaneously with 15 monoclonal antibodies against chicken IP3K in parallel lanes (see "Experimental Procedures"). In panel A the immunoreactivity of the monoclonal antibodies toward NH2-terminally truncated 31- and 16-kDa fragments of chicken IP3K, resulting from a tryptic digest in the absence of InsP3, is shown; in panel B a tryptic digest in the presence of 250 µM InsP3 with defined, NH2-terminally truncated 31- and 21-kDa fragments was used. In panels C-E the immunoreactivity toward COOH-terminally truncated GST-IP3K fusion proteins is shown, using crude bacterial lysates containing IP3K fragments comprising amino acids 164-317 in panel C, 164-289 in panel D, and 164-285 in panel E. The positions of the expected fragments are indicated in the right margin; positions and molecular masses of marker proteins are indicated in the left margin. Lane numbering corresponds to the number of the respective antibody used to incubate the membrane strip. FP, GST-IP3K fusion protein. In panel F, identical amounts of the lysates used in panels C-E were blotted and incubated with an anti-GST antibody to ensure the expression of the truncated fusion proteins. Lane A contains the fragment 164-289; lane B, fragment 164-317; and lane C, fragment 164-285.

In enzyme assays performed with IP3K147-C under Vmax conditions for both substrates in the presence and absence of antibodies, all antibodies inhibited IP3K activity by at least 30% and up to 70% when they were present at a molar ratios of 0.7 to 3, antibody binding sites to IP3K (Fig. 6). In all cases the observed inhibition clearly exceeded the inhibition of 11% measured in control reactions with a nonspecific antibody. To clarify the mechanism by which the antibodies exert their inhibitory effects on IP3K, two of the strongest binding antibodies (Kin4 binding to epitope A and Kin8 binding to epitope B) were selected for a determination of their effect on the Km values of IP3K. No direct effects on the Km values (derived from single transients, see Ref. 21) for InsP3 (Fig. 7A for Kin4, Fig. 7B for Kin8) and Km values for ATP (data not shown) were found but only Vmax effects. However, in experiments in which InsP4, acting as a competitive product inhibitor for InsP3, was included from the beginning at a concentration of 5 µM, Kin4 showed a synergistic effect with InsP4 in increasing the Km value for InsP3 (Fig. 7A), whereas Kin8 partially antagonized the effect of InsP4 on the Km value for InsP3 (Fig. 7B).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6.   Inhibition of IP3K activity by monoclonal antibodies. The percentage of inhibition of the IP3K activity by monoclonal antibodies was determined with enzymatic optical assays (see "Experimental Procedures") using 2.25-18 nM antibody and 6.68 nM IP3K (light gray columns). For the control reaction an anti-GST antibody was used at 4 nM. Results are means of at least three independent measurements, with S.D. indicated by error bars.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 7.   Influence of selected antibodies on Km for InsP3 in the presence of InsP4. Lineweaver-Burke plots are shown for measurements of IP3K activities with or without 5 µM InsP4 and with or without 4 nM Kin4 in panel A and Kin8 in panel B.

Amino Acids within the Region Protected from Proteolysis by InsP3 Contribute to InsP3 Binding-- To elucidate the role of individual amino acids in the cleavage protected region more thoroughly, we introduced several point mutations into this part and the neighboring segments of the protein. Most of these mutated residues are shown in Fig. 3. The mutant enzyme forms were bacterially expressed as IP3K147-C fragments, purified to about 70% homogeneity on phosphocellulose. Most were additionally affinity purified by CaM-Sepharose affinity chromatography (to >98% homogeneity) and then subjected to a detailed analysis of specific activity and Km values for both substrates. From 32 mutations generated, three (double mutant D240A/D241A, C254S, and R259N) obviously displayed aberrant folding behavior because the mutant proteins became entirely insoluble and therefore could not be studied further. Among the remaining 29 mutants, 12 turned out to have no significantly altered enzymatic properties compared with the wild-type enzyme. Three mutants, designed to reproduce previously described enzymatic knock-out mutants of rat IP3K isoform A (29, 30), also resulted in completely inactive enzymes (K255A, K255N, and D407S). Therefore, also in avian IP3K-A, Lys-255, (corresponding to Lys-262 in rat isoform A) and Asp-407 (corresponds to Asp-414 in rat isoform A) are indispensable for catalysis. However, a conservative substitution at the critical residue Lys-255 (K255R) displayed no enzymatic alterations against the wild-type (Fig. 8A-D), demonstrating that only a positively charged amino acid is essential at this particular position.


View larger version (59K):
[in this window]
[in a new window]
 
Fig. 8.   Enzymatic parameters of mutant IP3K proteins. In panel A the Km values for InsP3 determined for either phosphocellulose-purified or CaM-Sepharose-purified mutant IP3K proteins are presented. Results are means of at least three independent measurements, with S.D. indicated by error bars. Hatched bars indicate mutants with significantly increased and black bars mutants with decreased Km values for InsP3. In panel B the apparent rate constants (kcat) derived from Vmax/Km for InsP3 are depicted with their respective error bars. In panels C and D the specific activities and the Km values for ATP for CaM-Sepharose-purified mutant proteins are shown. Mutant proteins only purified by phosphocellulose chromatography are marked (*). Uninterrupted vertical lines indicate ± 1 S.D. or error range of the respective wild-type (WT36kDa) value, respectively. WT32kDa is a proteolytically shortened form of the recombinant protein, which was also purified by phosphocellulose chromatography.

With respect to ATP binding, five novel mutants (K176L, D245A, E247L, K327Q, and the double mutant D245A/E247L) showed significant elevations of the Km for ATP ranging from 1.6- to 2.1-fold (Fig. 8D), whereas their Km values for InsP3 remained nearly unchanged. These residues either lie between 23 and 94 amino acids upstream or 22 residues downstream of the protein region that is protected by InsP3 from proteolysis.

InsP3 binding was altered significantly in 10 mutants regarding eight residues (Fig. 8A), four of which (Lys-274, Arg-276, Lys-277, and Lys-303) lie within the InsP3-protected region, whereas two (Thr-267 and Arg-270) lie only four and one residue, respectively, upstream of the tryptic cleavage site in the InsP3-bound state of IP3K. The remaining two residues Arg-322 and Lys-327, on the other hand, lie 17 and 22 amino acids downstream of the InsP3-protected region.

The Km values for InsP3 of the mutants R276L, K303Q, and R322L display highly significant 11-, 16-, and 15-fold increases, respectively, compared with wild-type IP3K. Even the R276K and R322K mutations, which retain a positive charge at the respective positions, still have significantly (2.3-fold and 8.4-fold) increased Km values for InsP3. Although the maximal catalytic activities of mutants R276L and R276K equal or rather exceed that of the wild-type protein (Fig. 8C), mutants K303Q, as well as R322K, and R322L, display strongly impaired catalytic activity, with 3.8-33-fold lower Vmax values (all exhibiting p < 0.001) than wild-type (Fig. 8C). In particular, the conservative substitution in R322K, resulting in a 28-fold lower specific activity, indicates a strict requirement for arginine at this particular position for InsP3 binding and efficient catalysis.

Although not as evident as the above loss of function mutations, the Km values for InsP3 of five other mutants turned out to be equally interesting because they unexpectedly exhibited lower Km values for InsP3 (indicative of better substrate binding) than the wild-type. The mean apparent Km of these mutants for InsP3 is in all cases significantly (p < 0.005) reduced about 2-fold to between 0.3 and 0.35 µM compared with 0.69 µM for the wild-type. The increased apparent affinity of these mutants for InsP3 is also reflected (with the exception of K327Q) in their increased specific activities (Fig. 8C) and in their increased catalytic processivities (kcat), derived from Vmax/Km (Fig. 8B).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A 35-amino acid region almost in the middle of the 275-mino acid catalytic domain of chicken IP3K is protected from proteolysis in the InsP3-ligated enzyme. Apparently this segment of the enzyme containing the basic residues recognized by trypsin in the absence of InsP3 undergoes some major structural rearrangement upon InsP3 binding. The absence of large fragments derived from polypeptide Ala-191 to Arg-270 suggests an unfolding and further multiple cleavage of this segment when released. Whereas Arg-270, the cleavage site in front of the 21-kDa fragment and other more NH2-terminal sites, may always be exposed to proteolytic attack, Arg-305 and Arg-310 clearly become "protease-protected" in the presence of InsP3. Such protection implies that some of the residues within the protected region must be more or less directly involved in binding of InsP3 to the enzyme. The affinities of the proteolytic fragments for InsP3 can be inferred approximately from their EC50 values for protection against trytic attack. Whereas that for the 31-kDa band is only about 4-fold above the Km value for InsP3, that of the 21-kDa fragment is about 50-fold higher than Km. This means that although most of the structural components necessary for InsP3 ligation may be contained within the 21-kDa fragment, some residues within the upstream segment from Ala-191 to Arg-270 must also participate in InsP3 binding. For one residue, namely Lys-255, this has been directly proven by our mutational analysis. The participation of residues upstream of Lys-255 was made unlikely by previous studies (30).

The significant inhibitory effects of all antibodies binding to epitopes directly downstream of Arg-270 on the catalytic activity of IP3K could be the result of (i) a direct blocking or displacement of residues involved in catalysis, (ii) steric hindrance of the entry of substrates, or (iii) a general conformational inactivation of the enzyme. In the first two cases this would imply the direct participation of epitope-forming residues in InsP3 binding or their close proximity to the binding pocket. However, the inhibitory effect of the antibodies could not be attributed directly to an interference with InsP3 binding because no significant changes in the Km value for InsP3 were found in presence of selected strong inhibitory antibodies. Still, the observed interference of both subtypes of antibodies with binding of InsP4, exemplified with Kin4 and Kin8 indicates that their epitopes in either case may overlap with the InsP3/InsP4 substrate/product binding site and may constitute that part of the enzyme which interacts with the additional phosphate group of InsP4.

By mutational substitution of positively charged residues within the protease-protected region and the antibody epitopes we confirmed that Arg-276 and Lys-303 participate directly in InsP3 binding but not in ATP binding. How these basic residues interact with individual phosphates of substrate or product is clarified in ongoing substrate selectivity studies. A further indication that this segment of IP3K is mainly involved in inositol phosphate binding is the fact that seven other mutations within or close to this region also show effects on Km for InsP3 and therefore on InsP3 binding to the active site. The intriguing observation that five of these replacements promote rather than inhibit InsP3 binding needs to be clarified by three-dimensional structure determinations. As indicated by their increased kcat values, these mutants indeed represent artificially optimized versions of IP3K concerning catalytic processivity. It will be interesting to learn what has prevented the natural enzyme from evolving toward these forms.

Our results also support and complement previous findings that showed that Lys-262 in rat IP3K isoform A, corresponding to Lys-255 in our IP3K, is essential for catalysis and InsP3 binding (30). Our nonconservative mutations in this position did also abolish catalytic activity in chicken IP3K, whereas the conservative one did not (see "Results"). All of our additional mutations affecting InsP3 binding lie closely downstream of this apparent starting point of the InsP3 binding segment, identified by an NH2-terminal deletion of the rat isoform, corresponding to Leu-252 in our enzyme. We have now identified a total of eight amino acids involved in InsP3 binding, within a 73-amino acid segment from Lys-255 to Lys-327, covering also the segment protected by InsP3 binding against tryptic cleavage and the antibody epitopes (see Fig. 3).

Our studies also discovered the hitherto unknown participation in ATP binding of four residues (Lys-176, Asp-245, Glu-247, and Lys-327), which are all located outside this segment. Taken together with the residues described previously as being essential in ATP binding (29) it thus appears that two ATP binding segments, making up the NH2- and COOH-terminal ends of the catalytic domain, are flanking a central segment involved in InsP3 binding. In a previous study (30) short COOH-terminal truncations by up to nine amino acids led to an almost complete (1/3800) loss of enzyme activity, whereas InsP3 binding was only reduced by about 1 order of magnitude. This indicates that either enzyme activity or ATP binding depends strongly on the presence of a most likely helical intact COOH terminus. The much weaker influence of these truncations on InsP3 binding than on catalytic activity may be indicative of a more indirect facilitative, e.g. conformational, involvement of the COOH terminus in InsP3 binding and thus does not contradict the model of an InsP3 binding core segment.

The part of this segment encompassing residues 259-284 shows a distant similarity to a segment of the IP3R (24) (Fig. 9) containing four residues involved in InsP3 binding (8). In fact, the exchange of Arg-276 in IP3K and of the corresponding arginine residue in the IP3R has the same consequence: the reduction of InsP3 affinity (Fig. 9). Also, the mutation of Lys-268 in IP3K and of corresponding Lys-501 in IP3R has the same effect, namely no alteration of InsP3 affinity. The main differences regarding the effects of mutations are found for residues Arg-270, Lys-272, and Lys-274 of IP3K, which correspond to residues Arg-504, Arg-506, and Lys-508 of IP3R. Exchanges of these residues in IP3R reduce InsP3 affinity, whereas in IP3K they do not or even enhance it. Some differences between IP3K and IP3R regarding the mechanism of InsP3 binding are not unexpected because the enzymatic activity of IP3K, unlike IP3R, also requires an efficient release of the product InsP4. Nevertheless the partial correspondence of critical residues may reflect the existence of a type of InsP3 binding "core motif" common to IP3R and IP3K. Whether both are evolutionarily linked or a remarkable case of convergent evolution remains to be revealed by future genomic analysis.


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 9.   Sequence comparison of segments in IP3K and IP3R containing amino acids involved in InsP3 binding. Homologous residues within the segments are boxed. Residues that have been mutated are given as bold characters. The arrows are pointing to the amino acids that have been used for replacement. The effects of these mutations are indicated either by bold characters when InsP3 affinity was reduce or by normal characters when InsP3 binding was not influenced.

An intriguing recent observation even allowing further molecular dissection of this kinase into functional segments comes from a comparison of the recently identified sequences of InsP6 kinases (37, 38) with those of InsP3 kinases. The most conserved sequence between these inositol phosphate kinases is a short segment ranging from Pro-249 to Arg-259 in our IP3K (Fig. 3). This segment is in immediate continuity with the InsP3 binding core segment identified in this study. Comparing the latter segment between InsP3 and InsP6 kinases reveals only a minor degree of homology, which is not unexpected because of the differences between the two substrates InsP3 and InsP6. We therefore propose that the closely neighboring segment P-C-(VAI)-(ML)-D-X-K-(ML)-G has a common function in both inositol phosphate kinases, which may be the catalytic phosphate transfer from ATP to the inositol ring or the positioning of the ATP gamma -phosphate close to the acceptor hydroxyl of the inositol ring.

    ACKNOWLEDGEMENTS

We are grateful to Sigrid Poll for excellent technical assistance as well as to Dr. Gerhard Müller-Newen (RWTH Aachen, Germany) for help in constructing vector pGEX-SE1. We thank all students of the molecular biology courses of the Study Course Biochemistry/Molecular Biology of the University of Hamburg, who have contributed continuously to mutagenesis and expression of mutant proteins. In particular we thank students Anne Buschmann, Christian Buschmann, Ines Krohn, Dennis Pöpplau, and Tonio Wilcek for substantial contributions. We are indebted to Robin F. Irvine (University of Cambrigde, U. K.) and Adolfo Saiardi (Johns Hopkins University, Baltimore, MD) for providing us with manuscripts on InsP6 kinases before publication.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of a grant from the Graduiertenkolleg 336 of the Deutsche Forschungsgemeinschaft.

** Recipient of grants from the Deutsche Forschungsgemeinschaft. To whom correspondence should be addressed. Tel.: 49-40-42803-4639; Fax: 49-40-42803-6818.

    ABBREVIATIONS

The abbreviations used are: InsP3, inositol 1,4,5-trisphosphate; InsP4, inositol 1,3,4,5-tetrakisphosphate; IP3K, inositol 1,4,5-trisphosphate 3-kinase; IP3R, inositol 1,4,5-trisphosphate receptor; GST, glutathione S-transferase; DTT, dithiothreitol; PAGE, polyacrylamide gel electrophoresis; CaM, calmodulin; IP3K147-C, COOH-terminal fragment (amino acids 147-452) of chicken IP3K.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Cullen, P. J., Hsuan, J. J., Truong, O., Letcher, A. J., Jackson, T. R., Dawson, A. P., and Irvine, R. F. (1995) Nature 376, 527-530[CrossRef][Medline] [Order article via Infotrieve]
2. Fukuda, M., and Mikoshiba, K. (1997) BioEssays 19, 593-603[CrossRef][Medline] [Order article via Infotrieve]
3. Shears, S. B. (1998) Biochim. Biophys. Acta 1436, 49-67[Medline] [Order article via Infotrieve]
4. Mignery, G. A., Newton, C. L., Archer, B. T., III, and Sudhof, T. C. (1990) J. Biol. Chem. 265, 12679-12685[Abstract/Free Full Text]
5. Miyawaki, A., Furuichi, T., Maeda, N., and Mikoshiba, K. (1990) Neuron 5, 11-18[CrossRef][Medline] [Order article via Infotrieve]
6. Ross, C. A., Danoff, S. K., Schell, M. J., Snyder, S. H., and Ullrich, A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4265-4269[Abstract/Free Full Text]
7. Berridge, M. J. (1993) Nature 361, 315-325[CrossRef][Medline] [Order article via Infotrieve]
8. Yoshikawa, F., Morita, M., Monkawa, T., Michikawa, T., Furuichi, T., and Mikoshiba, K. (1996) J. Biol. Chem. 271, 18277-18284[Abstract/Free Full Text]
9. Mourey, R. J., Estevez, V. A., Marecek, J. F., Barrow, R. K., Prestwich, G. D., and Snyder, S. H. (1993) Biochemistry 32, 1719-1726[CrossRef][Medline] [Order article via Infotrieve]
10. Woscholski, R., and Parker, P. (1997) Trends Biochem. Sci. 22, 427-431[CrossRef][Medline] [Order article via Infotrieve]
11. Erneux, C., Govaerts, C., Communi, D., and Pesesse, X. (1998) Biochim. Biophys. Acta 1436, 185-199[Medline] [Order article via Infotrieve]
12. Jefferson, A. B., and Majerus, P. W. (1996) Biochemisty 35, 7890-7894[CrossRef][Medline] [Order article via Infotrieve]
13. Kanematsu, T., Takeya, H., Watanabe, Y., Ozaki, S., Yoshida, M., Koga, T., Iwanaga, S., and Hirata, M. (1992) J. Biol. Chem. 267, 6518-6525[Abstract/Free Full Text]
14. Kanematsu, T., Misumi, Y., Watanabe, Y., Ozaki, S., Koga, T., Iwanaga, S., Ikehara, Y., and Hirata, M. (1996) Biochem. J. 313, 319-325
15. Ferguson, K. M., Lemmon, M. A., Schlessinger, J., and Sigler, P. B. (1995) Cell 83, 1037-1046[CrossRef][Medline] [Order article via Infotrieve]
16. Irvine, R. F., Letcher, A. J., Heslop, J. P., and Berridge, M. J. (1986) Nature 320, 631-634[CrossRef][Medline] [Order article via Infotrieve]
17. Ryu, S. H., Lee, S. Y., Lee, K. Y., and Rhee, S. G. (1987) FASEB J. 1, 388-393[Abstract]
18. D'Santos, C., Communi, D., Ludgate, M., Vanweyenberg, V., Takazawa, K., and Erneux, C. (1994) Cell Signal 6, 335-344[CrossRef][Medline] [Order article via Infotrieve]
19. Foster, P. S., Hogan, S. P., Hansbro, P. M., O'Brien, R., Potter, B. V., Ozaki, S., and Denborough, M. A. (1994) Eur. J. Biochem. 222, 955-964[Medline] [Order article via Infotrieve]
20. Shin, Y. S., Choi, G., and Hoi, K. Y. (1995) Molecules Cells 5, 348-353
21. Bertsch, U., Haefs, M., Moller, M., Deschermeier, C., Fanick, W., Kitzerow, A., Ozaki, S., Meyer, H. E., and Mayr, G. W. (1999) Gene (Amst.) 228, 61-71[CrossRef][Medline] [Order article via Infotrieve]
22. Takazawa, K., Perret, J., DuMont, J. E., and Erneux, C. (1991) Biochem. Biophys. Res. Commun. 174, 529-535[CrossRef][Medline] [Order article via Infotrieve]
23. Takazawa, K., Perret, J., DuMont, J. E., and Erneux, C. (1991) Biochem. J. 278, 883-886
24. Choi, K. Y., Kim, H. K., Lee, S. Y., Moon, K. H., Sim, S. S., Kim, J. W., Chung, H. K., and Rhee, S. G. (1990) Science 248, 64-66[Abstract/Free Full Text]
25. Takazawa, K., VanDekerckhove, J., DuMont, J. E., and Erneux, C. (1990) Biochem. J 272, 107-112[Medline] [Order article via Infotrieve]
26. Thomas, S., Brake, B., Luzio, J. P., Stanley, K., and Banting, G. (1994) Biochim. Biophys. Acta 1220, 219-22[Medline] [Order article via Infotrieve]
27. Clandinin, T., DeModena, J., and Sternberg, P. (1998) Cell 92, 523-533[CrossRef][Medline] [Order article via Infotrieve]
28. Takazawa, K., and Erneux, C. (1991) Biochem. J. 280, 125-129
29. Communi, D., Takazawa, K., and Erneux, C. (1993) Biochem. J. 291, 811-816
30. Togashi, S., Takazawa, K., Endo, T., Erneux, C., and Onaya, T. (1997) Biochem. J. 326, 221-225
31. Hanahan, D. (1985) in DNA Cloning: A Practical Approach (Glover, D. M., ed) , p. 109, IRL Press Ltd., Oxford
32. Köhler, G., and Milstein, C. (1975) Nature 256, 495-49[CrossRef][Medline] [Order article via Infotrieve]
33. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467[Abstract/Free Full Text]
34. Kyhse-Andersen, J. (1984) J. Biochem. Biophys. Methods 10, 203-209[CrossRef][Medline] [Order article via Infotrieve]
35. Picard, V., Ersdal-Badju, E., Lu, A., and Bock, S. C. (1994) Nucleic Acids Res. 22, 2587-2591[Abstract/Free Full Text]
36. Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve]
37. Shell, M. J., Letcher, A. J., Brearley, C. A., Biber, J., Murer, H., and Irvine, R. F. (1999) FEBS Lett. 461, 169-172[CrossRef][Medline] [Order article via Infotrieve]
38. Saiardi, A., Erdjument-Bromage, H., Snowman, A. M., Tempst, P., and Snyder, S. H. (1999) Curr. Biol. 9, 1323-1326[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
G. W. Mayr, S. Windhorst, and K. Hillemeier
Antiproliferative Plant and Synthetic Polyphenolics Are Specific Inhibitors of Vertebrate Inositol-1,4,5-trisphosphate 3-Kinases and Inositol Polyphosphate Multikinase
J. Biol. Chem., April 8, 2005; 280(14): 13229 - 13240.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. M. Nalaskowski, U. Bertsch, W. Fanick, M. C. Stockebrand, H. Schmale, and G. W. Mayr
Rat Inositol 1,4,5-Trisphosphate 3-Kinase C Is Enzymatically Specialized for Basal Cellular Inositol Trisphosphate Phosphorylation and Shuttles Actively between Nucleus and Cytoplasm
J. Biol. Chem., May 23, 2003; 278(22): 19765 - 19776.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-C. Chang, A. L. Miller, Y. Feng, S. R. Wente, and P. W. Majerus
The Human Homolog of the Rat Inositol Phosphate Multikinase Is an Inositol 1,3,4,6-Tetrakisphosphate 5-Kinase
J. Biol. Chem., November 8, 2002; 277(46): 43836 - 43843.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Saiardi, E. Nagata, H. R. Luo, A. Sawa, X. Luo, A. M. Snowman, and S. H. Snyder
Mammalian inositol polyphosphate multikinase synthesizes inositol 1,4,5-trisphosphate and an inositol pyrophosphate
PNAS, February 8, 2001; (2001) 41614598.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Sai